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Abstract
Zambia has substantially been affected by the HIV/AIDS epidemic with prevalence rates at 14%
in a population estimated at 12 million. Yet, the extent of HIV-associated neurocognitive disorders
(HAND) in this population remains to be clearly understood. A series of culturally appropriate
neuropsychological (NP) assessments [International HIV Dementia Scale (IHDS), Color Trails
Test 1 and 2, Grooved pegboard Test, and Time Gait Test] were used to test the effects of HIV on
NP performance of HIV seropositive and seronegative individuals. Twenty-two percent HIV
positive individuals ARV naïve met the criteria for IHDS-defined NP impairment. Gender
significantly influenced the performance on NP tests with females performing more poorly
compared to males. Larger studies that will accommodate gender differences and age are
necessary to generate appropriate norms in Zambia in order to better assess the prevalence of
HAND in the developing country setting.
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Introduction
The global HIV epidemic has been most devastating in sub-Saharan Africa in which two-
thirds of the estimated 33.3 million of the HIV infected individuals reside [1]. One of the
major challenges of the HIV epidemic is that there are surmountable medical complications
[2] along with neurocognitive disorders [3]. In Western/developed countries, there is now a
better appreciation for the effects of HIV on cognitive function. Initially, the
neuropsychological (NP) profile was classified as a constellation of symptoms recognized as
HIV associated dementia that manifested as cognitive, motor, and behavioral abnormalities
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in AIDS patients [4], with a yearly incidence rate of 7.3% [5]. Over the years and with the
introduction of antiretroviral therapies (ARV) it became clearer that HIV infection leads to
progressive impairment in brain function [6-9]. Since then, the description has been refined
to include three main categories that ranged from less severe to more severe symptoms
classified as HIV-associated asymptomatic neurocognitive impairment (ANI), HIV
associated mild neurocognitive disorder (MND), and HIV associated dementia (HAD)
collectively referred to as HIV-associated neurocognitive disorders or HAND [3]. The
aforementioned literature is derived from regions where HIV subtype B predominates,
however, less is known in other parts of the world where the epidemic is most concentrated,
as in the case in sub-Saharan Africa.
Over the last 20 years, though sporadic, there are studies that addressed HIV associated
neurocognitive impairment prevalence in sub-Saharan Africa with a wide range of HAND
prevalence rates of 3.2-56% [8, 10-17]. This can be partly attributed to the methodological
approaches of earlier studies that were based mostly on clinical assessments to determine
HIV associated neurological and neurocognitive impairments [10-12]. The studies that
followed used a series of culturally adapted NP assessments to screen for evidence of
HAND [13, 14, 18, 19].
More recently, a few studies have investigated the neurological and neuropsychological
impairments of HIV infected individuals from subtype C HIV predominant regions [20-23].
However, there were conflicting results regarding evidence for marked HAND. A study
from Ethiopia concluded that for the exception of impaired psychomotor function, no
marked cognitive disorders were evident in a predominately asymptomatic cohort [20]. In
contrast, a study from South Africa reported a 23.5% HAND prevalence [22] defined by the
HIV Dementia Scale (HDS) [24, 25]. Furthermore, a recent study from Botswana [21]
reported that 38% of HIV infected individuals primarily on ARV treatment (97.5%)
presented with HAND symptoms defined by the IHDS [18]. There are impoverished regions
in sub-Saharan Africa in which HIV is endemic yet little is known about the effects of HIV
on neurocognitive function such as in Zambia.
Zambia, a low income country and one of the poorest countries in sub-Saharan Africa (2005
Human Development Report), has been considerably affected by the HIV epidemic with
prevalence rates of 14% in a population of 12 million [1, 26]. In Zambia, HIV subtype C is
prevalent but the neurological and psychological effects of HIV are not defined. This is
attributable to the lack of NP tools in this area as well as a lack of properly trained personnel
to administer NP tests to patients. Furthermore, since 2002 ARV treatment has become
available in Zambia and treatment programs were scaled up over the past several years [27].
The common regimen includes a combination of anti-retroviral regimen that consists of two
nucleoside reverse transcriptase inhibitors (NRTI) and one non-NRTI, collectively referred
to Trimune30. A recent study reported that HAND persists in the milder categories (ANI
and MND) and to a lesser extent in the more severe form of HAD regardless of combination
ARV treatment or CART [28]. Although the scaling up of ARV continues in developing
countries in Zambia the effects of ARV treatment on neurcognitive function remain to be
determined. Furthermore, the degree of HAND in asymptomatic and symptomatic
individuals living in this country has not been systematically investigated. Thus, the overall
objective in this study was to determine if evidence of HAND was present in a randomly
selected cohort from a primarily subtype C region and a low resource country setting.
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Methods
Study Site
This project was a collaborative effort between the United States (University of Nebraska,
Lincoln (UNL) and University of Miami Leonard Miller School of Medicine and Zambia
[University Teaching Hospital (UTH) and the University of Zambia (UNZA)]. The training
of Zambian medical professionals and study were carried out at the UTH and Our Lady
Hospice in Lusaka, Zambia.
Ethical Considerations
The UNL Institutional Review Board as well as the UNZA research ethics committee
approved all procedures. Written consent was obtained from the participants before any
procedures were performed. If the subject was a minor, written consent was obtained from
the participant’ s parent and verbal consent from the minor as per requirements of the
Zambian research ethics committees.
Training of Neuropsychological Administration in Zambia
A series of workshops and training sessions were developed at UTH to train local medical
professionals in administering the series of NP tests. A U.S. based psychologist (EW) with
expertise in NP assessment conducted the training. Nurses were recruited from the UTH
adult wards and Our Lady Hospice in Kalingalinga.
The training spanned for approximately 2 months during which time the nurses were
introduced to the testing materials and guidelines for administration of the measures. The
nurses were required to demonstrate clinical competence by achieving an error score of
<10% on test administration checklists according to the procedures outlined by Sattler for
training new examiners [29]. Focus group sessions were organized to further validate the
efficacy of the NP administration in the Zambian setting. The NP assessment was
approximately 35-45 min in duration.
Subjects
Participants were recruited by referral through the collaborating medical doctors at UTH
(MB, CM, and KOC) and an established community worker network to recruit both HIV
positive and negative individuals from the periods of March 2008 through October 2008.
The community worker network, established at UTH for the last 13 years, was utilized to
recruit participants from the volunteer counseling HIV testing centers, community clinics,
and compounds. Additionally, participants were also recruited from a private outpatient/
inpatient clinic Our Lady Hospice by referral from MB. Participants were from 33 different
townships distributed throughout Lusaka.
One hundred and forty-one HIV positive and negative participants were recruited.
Participants received a full medical examination that included a physical, neurological, and
psychological exam. General physical questions included, but were not limited to, history of
brain injuries, diseases (i.e., tuberculosis, malaria, syphilis, diabetes, epilepsy, etc.),
hospitalizations, surgeries, and alternative/traditional medicine. Additionally, questions also
included queries related to social habits such as intake and frequency of alcohol (Care-
Angry-Guilt-Eye opener survey), smoking and drugs. The psychological examination
included, but was not limited to, queries of general appearance, social interactions, affect,
mood, speech, thought process, perception, and orientation. The neurological examination
included queries related to motor (i.e., movement, muscle bulk, reflex, power, co-ordination
and sensation), orientation, and balance, in addition to full examination of the cranial nerves.
Additionally, an adapted mini mental state examination was used to screen for general
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dementia [30, 31]. Furthermore, a history of ARV treatment was documented if the
individual was HIV positive.
Neuropsychological (NP) Tests
The series of NP tests are short assessments that screen for sub-cortical dementia
[International HIV Dementia Scale (IHDS)] [18], speed processing/attention and executive
function [Color Trail Tests (CTT) 1 and 2] [32], and motor functions, both fine [Grooved
Pegboard Test (GPT)] and gross (Time Gait Test) [33, 34]. The IHDS consists of four tasks
that screen for acquisition, memory recall, motor speed, and psychomotor speed and a score
between 1 (poor) to 4 (best) was possible for each task [18]. All other tasks were scored
according to time speeds measured in seconds (sec).
Serology
Five milliliters (ml) of blood was collected into sterile EDTA vacutainers (BD, USA).
HIV-1 serostatus was verified using rapid HIV-1/2 test kits (Determine HIV 1/2, Abbott
Laboratories). HIV serostatus was confirmed with HIV UniGold rapid test (Trinity Biotech,
PLC). Laboratory assays were performed to detect antibodies against bacteria and parasites
that cause syphilis or malaria, respectively.
Inclusion and Exclusion Criteria
Participants had to speak and understand English, Nyanja, or Bemba. The participants’ main
residences were within Lusaka province. This criterion was set because residents of Lusaka
speak a looser Nyanja and Bemba, which are highly intermixed with English, whereas those
individuals that mainly reside in the villages outside the city area speak a more traditional
Nyanja (and/or Bemba). The translations were sensitive to these regional differences in
language. All assessment related instructions and tasks were translated from English to
Nyanja or Bemba and then reverse translated. Reverse translations were verified at the
University of Miami, Miller School of Medicine. Exclusion criteria included history of brain
injuries, concussions, and/or concomitant diseases (e.g., malaria, tuberculosis or syphilis).
Also, a participant was excluded if the age was below 16 years old.
Statistical Analysis
The data were entered into ACCESS file and then transferred to SPSS version 19 for data
analysis. The series of NP tests were evaluated to compare HIV status that accounted for
covariance of sociodemographics and clinical symptoms using a multiple covariate analysis
of variance (MANCOVA). A Z-test for proportions was applied to determine the statistical
significance of the percent differences on IHDS performance using a confidence level of
90%.
Results
There were 57 HIV seronegative (HIV− group), 54 HIV seropositive ARV naïve (HIV+
group), and 29 HIV-1 seropositive on ARV treatment (ARV group). The data was normally
distributed. Social demographic parameters are shown on Table 1. According to the WHO
clinical staging (CS) criteria [35] 49 were classified as CS 1, four as CS 3, and one as CS 4.
In the ARV group 24 were classified as CS 1 and five as CS 3. There were no stage 2
classifications in this cohort. There was no evidence of malaria or syphilis from individuals
who had blood specimens available for testing.
At a cut-off score of 10 the IHDS sensitivity is maximized at 80% with fewer false negatives
and achieves a specificity of 55% [18]. Using the HIV− group’ s data to normalize the HIV+
group’ s data to account for non-specific effects [18], it was found that 22% of HIV+ ARV
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naïve individuals met the classification of IHDS-defined impairment. When the HIV+ and
HIV− groups were compared to each other, it was found that 67% (36/54) of the HIV+
group fell at or below the cut-off point and this was significantly higher compared to 52%
(30/57) of the HIV− group (z = 1.31, 90% confidence level). Gender influenced the IHDS
performance with significant differences between the HIV+ females and males. Eighty
percent (28/35) of females scored at or below the cut-off point compared to 42% (8/19) of
the males (z = 2.51, 99% confidence level). No other significant differences were observed.
A MANCOVA was applied to correlate HIV status with sociodemographics (age, sex,
education) and clinical symptoms as covariates for the series of NP tests. The age category
was classified into two groups 18-35 and >36 [26]. Clinical symptoms were assigned a
categorical value of 1 (symptom(s) not present) or 2 (symptom(s) present) [36]. The
MANCOVA revealed significant differences of HIV status with covariance of sex as the
strongest cofactor that significantly influenced NP performance with age showing some
trends towards significance in the CTT 2 and GPTdom tasks (Table 2).
Discussion
There are two major findings in the present study. First, 22% of the HIV positive ARV naïve
individuals demonstrated HAND according to IHDS-defined NP impairment, which
suggests an underlying sub-cortical dementia. Second, the IHDS performance was greatly
influenced by gender wherein NP impairment was more prevalent in females compared to
the males.
The rate of prevalence of HAND reported here are lower compared to other studies from
sub-Saharan Africa. A recent pilot study from Botswana reported that 38% of the HIV-
infected individuals revealed HAND [21] defined by the IHDS [18]. The studies differed in
that the Botswana cohort was mostly on ARV treatment (97%) and also evaluation of NP
impairment was based on an IHDS cut-off point of 9.5 [21]. A study from South Africa
reported rates of 24% NP impairment [22] defined by the HIV Dementia Scale (HDS) [24,
25]. It was noted that co-factors such as age, education, alcohol abuse, and post-traumatic
stress disorder were associated with poor NP performance. A subsequent study of HIV
positive individuals that were to commence ARV treatment had a high prevalence of
HAND, specifically, 42.4% with MND and 25.4% with HAD. Again, co-factors of
education and age contributed to the prevalence of HAND [23]. In the present study,
although the medical examination included questions on alcohol intake and substance abuse
there were very few responses. Hence, the influencing effects of alcohol intake and drug
abuse may have gone undetected in the present study since it was not possible to include
these factors as covariates in the analyses.
The NP impairment observed here appeared to be gender biased as females showed a higher
rate of NP impairment as compared to the males. This observation was consistent
throughout the series of NP tests in which females performed more poorly than males. A
small collection of studies on gender and HIV show conflicting findings with some
concluding no gender differences [37-40] and others suggesting that there is a higher risk for
females in acquiring AIDS dementia complex [38] or that women manifest neurologic
symptoms earlier than men [41]. Interestingly, most studies that do not show evidence for
neuropsychological decline in asymptomatic patients are mostly comprised of male subjects
[36, 42]. More recently, however, Joska et al. [23] found that males and lower education
were significant predictors of HAD symptoms. It remains unclear why female and male
participants from this study differed in their performance as no differences were found in
their medical evaluation. In sub-Saharan Africa females have a higher rate of HIV infections
[1] and with the recent gender differences unraveling in NP assessments future studies
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should also examine the performance of genders independently with corresponding
normative data.
In the present study it was also shown that ARV treatment did not have any significant
effects except for slower scores in gross motor function (TGT). This may be due to a higher
number of older participants in the ARV treated group than the HIV− and HIV+ ARV naïve
groups. In Zambia, the peak age for HIV infection is mid-thirties [43] and this may be
attributed to the older individuals in the ARV group.
It is established that associations exist between HIV disease and the ability to perform daily
functions and/or fulfill occupational duties [7]. Furthermore, higher rates of unemployment
are associated with HIV disease and poor performance on functional and neuropsychological
tests. Our study did not survey daily living activities but occupational demographics showed
that the unemployment rates were comparable between the HIV infected and uninfected
groups. Formal occupations included that of teachers, electricians, and secretaries. However,
there was also a high rate of informal work/occupations. The types of occupations that were
common included those of maids, gardeners, security guards, drivers (taxi/bus) and market
vendors (selling food). It is worth noting that these occupations are gender specific in the
setting. In Zambia, there is an unemployment rate of 14% and with the higher rates in the
urban cities, especially in Lusaka with a rate of 31% (www.zamstats.gov.zm). The inability
to perform daily living activities and meet the demands of an occupation is not only a health/
mental status concern but is also critical for the development of a country.
A caveat worth noting, since the HIV− group showed a little over 50% that scored at the
cut-off point on the IHDS the prevalence of HAND in Zambia may be lower than the
reported levels if factors such as age, gender, and social habits (alcohol abuse or drug abuse)
are normalized. However, the sample size was limiting to formulate normative values. This
limitation, also, may have influenced the unexpected outcome of the control group’ s
performance on tasks of motor, attention, and dual processing functions. Additionally,
although the IHDS Total mean score showed the same trend as the percent difference group
comparisons in which the HIV+ group performed more poorly compared to the HIV− group,
the sample size limited statistical power. Another limitation of this study is that the HIV−
group was significantly younger than the HIV+ group though the age range was equally
represented across the groups. NP performance and CD4 count associations remain
controversial and though in the present study an attempt to collect blood specimens at the
time of assessment was made, there were still too few samples to analyze and derive
meaningful associations between the serological measures (CD4 count and viral load levels)
and NP performance. The evaluation of immunological data is critical in comparing HIV
infected individuals to “healthy” controls. Though Zambia is a region with high prevalence
of malaria the negative results for parasitemia in our cohort appeared to be unusual.
Nonetheless, no clinical signs were found to suggest an ongoing malaria or syphilis episode
at time of the study visit.
Conclusion
The present study is the first to systematically assess NP performance administered by
trained NP examiners in Zambia. It was found that HAND is present in HIV positive
individuals in Zambia where subtype C infection is prevalent. However, the lack of
normative data remains a challenge in the developing country setting. Since NP testing is
now feasible in Zambia, future studies should include additional assessments that measure
memory and language skills to achieve a more comprehensive neuropsychological profile to
further examine the prevalence of HAND.
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